Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03699475 | Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS(THRIVE) | terminated | Phase 2 / Phase 3 | 1 | Bellicum PharmaceuticalsINDUSTRY | 1 | Sep 29, 2023 | clinicaltrials |
| NCT03733249 | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | terminated | Phase 1 / Phase 2 | 187 | Bellicum PharmaceuticalsINDUSTRY | 1 | Sep 26, 2023 |
| clinicaltrials |
| NCT03067571 | Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04002115 | Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML | terminated | Phase 2 | 2 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT04079738 | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib | terminated | Phase 1 / Phase 2 | 8 | H Scott BoswellOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | terminated | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT02935543 | CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL | terminated | Phase 2 | 1 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03634228 | Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03705507 | International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia(SeluDex) | terminated | Phase 1 / Phase 2 | 12 | University of BirminghamOTHER | 3 | May 11, 2023 | clinicaltrials |
| NCT02323113 | Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 43 | Calithera Biosciences, IncINDUSTRY | 2 | Feb 8, 2023 | clinicaltrials |
| NCT04225676 | Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 2 | 5 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 30, 2023 | clinicaltrials |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 46 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT03214666 | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | terminated | Phase 1 / Phase 2 | 12 | GT Biopharma, Inc.INDUSTRY | 1 | Nov 10, 2022 | clinicaltrials |
| NCT03518112 | Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT04425655 | Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. | terminated | Phase 2 | 2 | University of California, San DiegoOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT01440179 | SAR3419 in Acute Lymphoblastic Leukemia(MYRALL) | terminated | Phase 2 | 100 | SanofiINDUSTRY | 2 | Sep 21, 2022 | clinicaltrials |
| NCT03760666 | A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 17 | Clear Creek Bio, Inc.INDUSTRY | 1 | Aug 8, 2022 | clinicaltrials |
| NCT02773732 | Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101) | terminated | Phase 1 / Phase 2 | 11 | University of FloridaOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT01773395 | GVAX vs. Placebo for MDS/AML After Allo HSCT | terminated | Phase 2 | 123 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 18, 2022 | clinicaltrials |
| NCT01640301 | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 47 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 14, 2022 | clinicaltrials |
| NCT00961142 | Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia(CD3/CD19 Haplo) | terminated | Phase 2 | 23 | University Hospital TuebingenOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT01177540 | Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects | terminated | Phase 2 | 25 | Eisai Inc.INDUSTRY | 3 | Jun 28, 2022 | clinicaltrials |
| NCT04326439 | AflacLL1901 (CHOA-AML) | terminated | Phase 2 | 8 | Emory UniversityOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT03063203 | Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 2 | 17 | Washington University School of MedicineOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT02043587 | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | terminated | Phase 2 | 31 | University of California, San DiegoOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT00968864 | T-cell Depleted Alternative Donor Transplantation | terminated | Phase 2 | 53 | Wake Forest University Health SciencesOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT03600909 | A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia | terminated | Phase 2 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01876953 | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03668392 | Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL)(ALL2518) | terminated | Phase 2 | 7 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04044560 | Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant(OZM-097) | terminated | Phase 2 | 8 | University of British ColumbiaOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT03951961 | Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation | terminated | Phase 2 | 1 | University of JenaOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | terminated | Phase 1 / Phase 2 | 8 | AGC Biologics S.p.A.INDUSTRY | 2 | Jan 19, 2022 | clinicaltrials |
| NCT03557970 | JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 2 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT02795520 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 32 | OncoTherapy Science, Inc.INDUSTRY | 1 | Nov 24, 2021 | clinicaltrials |
| NCT01620216 | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | terminated | Phase 2 | 12 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT02770820 | Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 9 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT04051996 | GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia | terminated | Phase 2 | 1 | Yale UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT03742323 | REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 6 | PETHEMA FoundationOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02229266 | Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML(HINKL) | terminated | Phase 2 | 1 | Technische Universität DresdenOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01113502 | Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 44 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT02440568 | AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients | terminated | Phase 1 / Phase 2 | 22 | University of Illinois at ChicagoOTHER | 1 | Jul 6, 2021 | clinicaltrials |
| NCT01486784 | A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 27 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT03094611 | Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT00439296 | ABT-751 With Chemotherapy for Relapsed Pediatric ALL | terminated | Phase 1 / Phase 2 | 9 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT03113071 | Safety and Activity of Digoxin With Decitabine in Adult AML and MDS | terminated | Phase 1 / Phase 2 | 1 | Fox Chase Cancer CenterOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT00615784 | Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia(UPCC04407) | terminated | Phase 2 | 24 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 17, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Sep 29, 2023source: clinicaltrials